In conclusion, genetic ablation of Elovl1 combined with anti-PD-1 treatment improves CD8+ T cell activation and functionality in the immune-suppressive microenvironment of pancreatic cancer. The gene discussed is ELOVL1; the disease is familial pancreatic carcinoma.